N-PORT filing recap · April 2024

What did ARK Genomic Revolution ETF buy in April 2024?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.31B

Positions

Estimated turnover

13.7%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

NTRANatera, Inc.$7.69Mreported value+82.8K shares

Increased positions

CRSPCrispr Therapeutics AG$92.31Mreported value+5.9K shares+0.3%TWSTTwist Bioscience Corporation$88.90Mreported value+184.3K shares+6.9%RXRXRecursion Pharmaceuticals, Inc.$71.97Mreported value+589.0K shares+6.8%NTLAIntellia Therapeutics, Inc.$51.57Mreported value+336.4K shares

Reduced positions

EXASExact Sciences Corporation$69.03Mreported value-906.7K shares-43.8%SDGRSchrodinger, Inc.$61.42Mreported value-71.4K shares-2.8%IONSIonis Pharmaceuticals, Inc.$57.77Mreported value-71.2K shares-4.8%BEAMBeam Therapeutics Inc.$45.63Mreported value-54.3K shares

Exited positions

NVDANvidia Corp$20.40Mprior reported value-33.2K shares-100.0%NVTAInvitae Corp$3.26Mprior reported value-8.35M shares-100.0%PFEPfizer Inc.$3.20Mprior reported value-118.3K shares-100.0%